Mallinckrodt launches MRI (magnetic resonance imaging) contrast injectors in US:
This article was originally published in Clinica
Executive Summary
Mallinckrodt is launching its Liebel-Flarsheim Optistar MRI contrast agent delivery system in the US following its approval by the FDA in December. The product is also being sold in Canada. The power injector system allows for pre-programming for individual patients, as well as contrast and saline rate control. The company estimates that the power injector market is worth $35 million.